Brachytherapy Benefits in High-Risk Prostate CancerBrachytherapy Benefits in High-Risk Prostate Cancer
Brachytherapy after external beam radiotherapy (EBRT) doubles the chance of progression-free survival at 9 years when compared with EBRT alone. Medscape Medical News
AbstractObjectiveThere is a paucity of clinical data to support the hypothesis that external beam radiation therapy causes iatrogenic hypogonadism in prostate cancer patients.MethodsAll prostate cancer patients treated at a single institution with radiation therapy between 2002 and 2010 were retrospectively evaluated. Patients treated with brachytherapy alone received 0 Gy of external beam radiation therapy and served as the control group. Patients treated with combination external beam radiation therapy + brachytherapy, or external beam radiation therapy alone were categorized into groups who received 45–54&nb...
To evaluate the long-term urinary outcomes of men with severe pretreatment lower urinary tract symptoms (LUTS) treated with permanent prostate brachytherapy (PPB) ± external beam radiation therapy for localized prostate cancer.
This study aimed to test the hypothesis that patients with prostate cancer with intermediate- or high-risk disease undergoing extreme dose escalation with a brachytherapy boost are less likely to receive ADT.
ConclusionssRP was safe, feasible, and effective using either an open or robot-assisted approach, in experienced hands. Age, preoperative clinical stage, NS procedure, and pathological GS were linked with BCR after sRP.
Condition: Prostate Cancer Intervention: Radiation: LDR Brachytherapy and External Beam Radiation Therapy Sponsor: British Columbia Cancer Agency Not yet recruiting
CONCLUSIONS: The model applies to high-risk RT patients; GS 9-10 remains a powerful predictor of PCSM. Comparing similar prognosis patients, CMRT is associated with improved disease-specific outcomes relative to EBRT. In poor-prognosis patients, CMRT+LTADT yields superior 10-year PCSM, potentially improving RT treatment personalization for those with HRPC. PMID: 30724780 [PubMed - as supplied by publisher]
AbstractPurposeTo analyze outcomes and complication rates in an unselected cohort of men with unfavorable (NCCN intermediate and high-risk) PCa receiving combined-modality radiation treatment (CRT).MethodsPatients received androgen deprivation therapy for 1 year and combined-modality radiation treatment (CRT) consisting of external-beam radiotherapy (EBRT, 59.4 Gy, 33 fractions) and125J seed-brachytherapy (S-BT, 100 Gy). Subgroups, including WHO group 3–5, and initial PSA (iPSA) 20 ng/ml were identified. Biochemical recurrence-free (BRFS), metastasis-free (MFS), cancer-specific (...
ConclusionS-HIFU and S-RP could both be considered valuable LST options for patients with radiation-recurrent nonmetastatic PCa with sufficient life expectancy. S-RP is associated with more pad-dependent patients at 12 months.
Publication date: Available online 19 January 2019Source: European UrologyAuthor(s): Alexander P. Cole, Quoc-Dien Trinh
Publication date: Available online 19 January 2019Source: European UrologyAuthor(s): Amar U. Kishan, William A. Hall, Daniel E. Spratt